United Therapeutics posts TETON-2 Phase 3 results for inhaled Tyvaso in IPF
Results for the completed 597-patient trial of inhaled treprostinil in idiopathic pulmonary fibrosis were posted to ClinicalTrials.gov on October 15, 2026.
United Therapeutics logged one update this week, the results posting for its Phase 3 trial of inhaled treprostinil in idiopathic pulmonary fibrosis.
- TETON-2 (NCT05255991) is a Phase 3, randomized, placebo-controlled trial testing inhaled treprostinil, also known as Tyvaso, against placebo for change in absolute forced vital capacity in subjects with idiopathic pulmonary fibrosis over a 52-week period.1 The study is listed as completed, with actual primary and study completion dated 2025-06-30, and enrolled 597 participants.1 Results were first posted on 2026-10-15, the same date as the last update.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.